Back to top
more

EyePoint Pharmaceuticals (EYPT)

(Delayed Data from NSDQ)

$11.59 USD

11.59
889,612

-0.55 (-4.53%)

Updated May 21, 2024 04:00 PM ET

After-Market: $11.57 -0.02 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 9.09% and 46.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Surges: Stock Moves 7.4% Higher

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 25.00% and 12.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Will EyePoint Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in EyePoint.

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 0.00% and -47.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 15.38% and 6.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -23.08% and -45.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 14.29% and 272.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: EyePoint Pharmaceuticals (EYPT) Q2 Earnings Expected to Decline

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.

    EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -46.15% and -30.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    Will EyePoint Pharmaceuticals (EYPT) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq

    by Zacks Equity Research

    EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.

      EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%

      by Zacks Equity Research

      EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

      Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options

      by Zacks Equity Research

      Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.

        EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          EyePoint Pharmaceuticals (EYPT) Q4 Earnings Preview: What to Know Ahead of the Release

          by Zacks Equity Research

          EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

            Will EyePoint Pharmaceuticals (EYPT) Continue to Surge Higher?

            by Zacks Equity Research

            As of late, it has definitely been a great time to be an investor in EyePoint Pharmaceuticals, Inc. (EYPT)